Form 4: Syndax Pharmaceuticals CEO Michael Metzger Acquires Shares and Stock Options

Michael Metzger, CEO of Syndax Pharmaceuticals, reports acquisition of common stock and stock options.

Summary

• On February 5, 2025, Michael Metzger, the CEO of Syndax Pharmaceuticals, acquired 60,500 shares of common stock and 89,000 shares of common stock.
• These shares were obtained through the award of restricted stock units (RSUs).
• One-third of the shares from the first RSU award will vest annually, contingent upon continued service.
• The number of shares acquired upon vesting of the second RSU award is contingent upon the achievement of pre-established performance metrics.
• Metzger also acquired stock options for 364,000 shares of common stock at an exercise price of $14.65, vesting monthly over four years, expiring on 02/05/2035.
• Following these transactions, Metzger beneficially owns 313,409 shares of common stock and stock options for 364,000 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine filing related to executive compensation. The acquisitions suggest confidence, but it's not overwhelmingly positive.

Positives

• The CEO's acquisition of shares and stock options could be interpreted as a positive signal, indicating confidence in the company's future performance.
• The vesting schedules for the RSUs and stock options incentivize continued service and achievement of performance metrics.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.

Stakeholder Impact

• The transactions could influence investor sentiment regarding the company's prospects.
• Employees may be motivated by the vesting of RSUs and stock options, aligning their interests with the company's success.

Key Dates